Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Year range
Preprint in English | EMBASE | ID: ppcovidwho-326897


The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in southern Africa has been characterised by three distinct waves. The first was associated with a mix of SARS-CoV-2 lineages, whilst the second and third waves were driven by the Beta and Delta variants respectively1–3. In November 2021, genomic surveillance teams in South Africa and Botswana detected a new SARS-CoV-2 variant associated with a rapid resurgence of infections in Gauteng Province, South Africa. Within three days of the first genome being uploaded, it was designated a variant of concern (Omicron) by the World Health Organization and, within three weeks, had been identified in 87 countries. The Omicron variant is exceptional for carrying over 30 mutations in the spike glycoprotein, predicted to influence antibody neutralization and spike function4. Here, we describe the genomic profile and early transmission dynamics of Omicron, highlighting the rapid spread in regions with high levels of population immunity.

Clinical Cancer Research ; 26(18 SUPPL), 2020.
Article in English | EMBASE | ID: covidwho-992016


Introduction and Objectives: Cancer patients are more susceptible to infections because of the active treatmentthat they need to treat their disease. A new coronavirus, called SARS-CoV-2, has caused a global pandemic wherecancer patients have an increased risk of morbidity and mortality associated with COVID-19. However, the incidencedata of COVID-19 in cancer patient with active treatment are not known, although the main oncology societiesrecommend a delay and/or stop in active cancer treatment during this pandemic. Whether this stop will have animpact on the future evolution of their disease is also not known. Therefore, a study of the incidence of COVID-19 inthis type of patient can help us to organize the protocols and the treatment in these high-risk patient group. Materials and Methods: We conducted a prospective clinical study of cancer patients within active treatment(chemotherapy, palliative hormonotherapy, radiotherapy, target therapies, or immunotherapy), analyzing the numberof COVID-19 diagnoses between February 26 and May 13 in two oncology services of the Andalusian community. Adescriptive analysis of 692 patients with active treatment was carried out. In addition, the cumulative incidence andthe differences between groups were calculated using the SPSS vs 18. Results: A total of 692 cancer patients undergoing active treatment at the Hospital Costa del Sol (Marbella) and atthe Hospital San Cecilio (Granada) were analyzed. Sixty four percent were men with a mean age of 60 years. Fortyone percent had a breast cancer diagnosis, 12.9% had lung cancer, and 14.5% had colorectal tumor. Fifty threepercent of them received treatment for stage IV disease, and up to 43% were delayed treatment due to pandemic.The total number of infections was 9, a cumulative incidence of 1.3%, 95% CI (0.384-2.217), and 22% of them diedafter developing the infection. Advanced age (p = 0.011), an admission in the 3 months prior to the diagnosis ofCOVID-19 (p = 0.031), and active treatment with chemotherapy (p = 0.003) were the factors that were associated with an increased risk of developing COVID-19. Conclusions: The incidence of SARS-CoV-2 in cancer patients on active treatment is low but the mortality is high, as previously reported for these patients. Given that the incidence of COVID-19 in patients with treatment is low, wecannot conclude any role of treatment delay in the development of COVID-19 in these patients..